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In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western
countries is KRAS, for which, however, there remains no clinically approved targeted
therapies. Recent progress on high biological heterogeneity including diverse KRAS point
mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring
genetic alterations, as well as distinct cellular status across the epithelial-to-mesenchymal
transition (EMT), has not only deepened our understanding about the pathobiology of
KRAS-mutant NSCLC but also brought about unprecedented new hopes for precision
treatment of patients. In this review, we provide an update on themost recent advances in
KRAS-mutant lung cancer, with a focus on mechanistic insights into tumor heterogeneity,
the potential clinic implications and new therapies on horizons tailored for KRAS-mutant
lung cancer.
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INTRODUCTION
Lung cancer is the most common cancer with high lethality (1). Carcinogenic Kirsten rat sarcoma
viral oncogene homolog (KRAS) mutation is the most common gain-of-function alteration,
accounting for ∼30% of lung adenocarcinomas in western countries and about 10% of Asian lung
adenocarcinomas (2).
As a membrane-bound small GTPase, KRAS switches between the active GTP-bound and
inactive GDP-bound status, which is regulated by guanine nucleotide exchange factors (GEFs)
and GTPase-activating proteins (GAPs), respectively (3). The intrinsic GTPase activity of RAS is
rather low, but in the presence of GAPs, such as neurofibromin 1 (NF1), its hydrolytic activity
can be increased by several orders of magnitude. Reactivation of GDP-bound RAS is mediated by
GEFs, such as son of sevenless homolog 1 (SOS1), which promotes the release of bound GDP, and
then cellular GTP will replace GDP to bind to RAS. Carcinogenic mutations impair the ability of
KRAS to hydrolyze GTP and are thought to lock the oncoprotein in a constitutively active state
by activating KRAS downstream signaling cascades, leading to uncontrolled cell proliferation and
survival. In patients with lung cancer harboring KRAS mutations, the most mutations occur in
codon 12, whereas mutations in codons 13 and 61 are less frequent (4).
In lung cancer, considerable progress in developing molecularly-driven therapeutics has
been made in the past decades, mainly including targeted therapies against oncogenic drivers,
such as EGFR, HER2, EML4-ALK, MET, ROS1, and BRAF mutations, and immunotherapies
in non-oncogene-driven lung cancer, such as PD1 and PDL1 alterations (5, 6). However, for
KRAS-mutant lung cancer, the treatment options are still limited, and chemotherapies remain the
first-line recommendation.
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In this review, we update the recent clinically relevant aspects
of the pathobiology of KRAS-mutant non-small cell lung cancer
(NSCLC), mainly focusing on tumor heterogeneity, therapeutic
implications, and new treatment opportunities.
HETEROGENEITY IN KRAS-MUTANT
LUNG CANCER
Diverse Point Mutations in KRAS
In lung cancer, KRAS mutations occur primarily in
adenocarcinoma, whereas they are only rarely seen in squamous
cell carcinoma (Figure 1). Diverse point mutations exist within
KRAS, the majority of which affect codon 12 of the protein in
NSCLC (Figure 1), leading to amino acid substitutions that
impair the intrinsic hydrolytic activity and render the KRAS
oncoprotein constitutively active.
In lung cancer, the presence of KRAS amino acid substitution
influences patients’ prognosis and is negatively associated with
patient response to targeted therapy (7, 8) and chemotherapy
(9–11). Molecular modeling studies showed that different
conformations imposed by distinct KRAS oncogene substitutions
could lead to altered association with downstream signaling
transducers (12). Specifically, compared to wild-type KRAS, the
mutant KRASG12C or KRASG12V is less dependent on AKT,
which, however, is more intimately engaged by other mutant
KRAS proteins.
Mutant KRAS with different amino acid substitutions may
also associate with distinct biological behavior (13) and can
lead to different clinical outcomes (14–16). In KRAS-mutant
lung cancer, tumors carrying KRASG12C exhibited higher ERK1/2
phosphorylation than those with KRASG12D (17). In supporting
this observation, studies with genetically engineered mouse
model showed that KrasG12C tumors were significantly more
sensitive to MEK inhibitor than the KrasG12D ones and that MEK
inhibition significantly increased chemotherapeutic efficacy and
progression-free survival (PFS) of KRASG12C mice.
Taken together, different amino acid substitutions in
oncogenic KRAS lead to heterogeneity in biological behaviors
of the mutant protein, implying the need of genotype-specific
analysis to identify clinically relevant subgroups of patients that
may ultimately influence treatment decisions. It also should be
taken into account for different downstream signaling pathways
to be inhibited for patients with tumors carrying different KRAS
amino acid substitutions.
KRAS Dependence Score and EMT
The concept ofKRAS dependence or independence was proposed
based on the observations that in both patients and cell lines,
tumors frequently exhibit unexplained intrinsic resistance to
KRAS-targeted therapy, by either inhibitors or genetic ablations.
Mutant KRAS has been considered as an oncogenic driver.
However, whether it is indispensable in each tumor carrying
this oncogene is not clear. Early evidence suggested that not
all KRAS-mutant tumor cells are dependent on KRAS (18, 19),
and that some KRAS-mutant cancer cells, including lung (20)
and pancreatic cancer cells (21, 22), can survive in the absence
of the KRAS oncogene. These observations provide additional
layers of evidence that make targeting KRAS-mutant tumors
more complex.
Oncogenic KRAS can activate various downstream effector
pathways, and the best characterized are phosphatidylinositol 3-
kinase (PI3K) and mitogen-activated protein kinases (MAPK)
(23–25). Oncogenic KRAS signaling proceeded by different
downstream effectors may lead to phenotypic variance in cancer,
but to what extent the downstream effectors contribute to
the oncogenic phenotype is not fully understood. Recently,
Yuan et al. designed a combinatorial siRNA-based approach
to functionally discern the link between KRAS downstream
effectors and phenotypic variation in a large panel of cancer
cell lines, and identified two major subtypes within KRAS-
mutant cancers based on the dependence on KRAS or RSK
(Ribosomal Protein S6 Kinase A1) (25). Interestingly, besides the
distinct morphologies and effector landscapes, the two subtypes
also differ in metabolic status with therapeutically tractable
vulnerabilities. The heterogeneity in effector signaling pathways
across KRAS-mutant cells presents a significant challenge to
identify universal synthetic partners lethal to mutant KRAS.
It is well-documented that the epithelial-to-mesenchymal
transition (EMT) process is closely related to therapy resistance.
Interestingly, KRAS-mutant cancer cells dependent on or
addicted to KRAS oncogene are more associated with an
epithelial phenotype, whereas those independent of KRAS
adopt a mesenchymal phenotype (18). Importantly, KRAS-
mutant cancer cells differing in EMT status vary in their
responses to MEK inhibitors (26), as EMT rewires the
expression of receptor tyrosine kinases (RTKs), a consequence
of differential feedback activation of the MAPK pathway
following MEK inhibition. In epithelial-like cancer cells, ERBB3
is preferentially activated by feedback signaling, which reactivates
MEK and AKT signaling. In mesenchymal-like KRAS-mutant
cancer cells, reactivation of MEK and AKT was dominantly
driven by FGFR1. Signaling transduced by FGFR is normally
suppressed by the sprouty proteins (SPRY4), but MEK inhibition
represses the negative regulation of SPRY4. In line with
this, another independent study using short hairpin (sh)
RNA screen had similar findings in KRAS-mutant lung and
pancreatic cancer cells (27). These findings provide a strong
therapeutic rationale to treat epithelial KRAS-mutant lung
cancer (high epithelial markers) with clinically available ERBB
and MEK inhibitors, and mesenchymal-like KRAS-mutant lung
cancers (high FGFR1) by combined therapy with FGFR and
MEK inhibitors.
The association of tumor response to MEK inhibitor therapy
to EMT status of cancer cells was further investigated by a more
recent study (28). Peng et al. identified an inverse correlation
between MAPK signaling dependency and a zinc finger E-box
binding homeobox 1 (ZEB1)–mediated EMT in patient samples
harboring KRAS, BRAF, or NRASmutations. Mechanistic results
indicated that MAPK dependency is dictated by the functional
interplay between scaffold protein interleukin-17 receptor D
(IL17RD) and ZEB1. Mechanistically, in mesenchymal-like
KRAS-mutant lung cancer cells, ZEB1 directly represses IL17RD
to mediate the resistance to MEK inhibitors. Based on this,
ZEB1 suppression by miR-200 expression or histone deacetylase
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FIGURE 1 | Frequency of KRAS missense mutations. The Cancer Genome Atlas (TCGA) primary lung adenocarcinoma (n = 489; A) and squamous cell carcinoma (n
= 492; B) cohorts, and Memorial Sloan Kettering Cancer Center (MSKCC) primary (n = 471; C) and metastatic lung adenocarcinoma (n = 444; D) cohorts.
inhibitor (mocetinostat) re-sensitized mesenchymal cells to
MEK inhibition and markedly reduced in vivo tumor growth.
This study provided the mechanistic support for combinatorial
treatment (MEK plus histone deacetylase inhibitors) for KRAS-
mutant lung cancer, and, again, highlighted the importance of
stratification of epithelial and mesenchymal subsets in decision-
making for treating KRAS-mutant lung cancer.
Genetic Alterations Co-occurring With
KRAS Mutations
Heterogeneity in KRAS-mutant tumors also arises from
co-occurring alterations of other genes, e.g., TP53, CDKN2A/2B,
STK11, andKEAP1 (Figure 2). Compelling evidence showed that
co-occurring genomic changes could profoundly affect biological
behaviors (29–31), clinical outcomes (32), and therapeutic
vulnerabilities of KRAS-mutant cancers (33, 34).
An integrative study of genomics, transcriptomics, and
proteomics in early-stage and chemo-refractory KRAS-mutant
lung adenocarcinomas identified three major subsets defined by
co-occurring genetic alterations in STK11/LKB1 (KL subgroup),
TP53 (KP subgroup), and CDKN2A/B (KC subgroup) (29). The
three subgroups differ in biological properties and therapeutic
vulnerabilities, with KC tumors associated with suppressed
mTORC1 signaling and KL tumors with lower expression of
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FIGURE 2 | Oncoprint for common genetic alterations co-occurring with KRAS in TCGA lung adenocarcinoma cohort. (A) The genetic landscape of KRAS, TP53,
KEAP1, CDKN2A, and STK11 in TCGA primary lung adenocarcinoma cohort (n = 489). (B) UpSetR plot visualizing the intersections of other mutations co-occurring
with KRAS-mutant across TCGA lung adenocarcinomas. The intersection points are indicated by different colors: CDKN2A (purple), KEAP1 (brown), STK11 (blue),
and TP53 (orange). Intersections among the co-occurring genes were connected with a line, with frequency of each co-occurring mutation type shown on the bar
plot. Set metadata is shown to the left (charts).
immune markers (e.g., PD-L1) if KEAP1 co-mutated, while
higher levels of somatic mutations, inflammatory and immune
checkpoint markers, and prolonged relapse-free survival were
observed in KP tumors. Further, KL cells exhibited heightened
vulnerability to HSP90 inhibition. This work argued that
genomic alterations co-occurring with mutant KRAS stratify
lung adenocarcinomas and define pathobiological properties and
therapeutic vulnerabilities.
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A more recent study of a large patient cohort (n = 330)
with advanced KRAS-mutant lung cancer identified co-mutated
KEAP1 as an independent prognostic marker for poorer survival
[HR = 1.96; P < 0.001] and as being associated with less
response to chemotherapy [HR = 1.64; P = 0.03] and immune
therapy [HR= 3.54; P = 0.003] (30). Another study showed that
presence of co-mutated Trp53 reduces sensitivity to combined
treatment with MEK inhibitor and chemotherapy in KrasG12C-
driven murine lung cancer, which supports further clinical
investigations of the combination therapy for patients with lung
cancer harboring KRASG12C and wild-type p53 (17). Finally,
yet importantly, STK11/LKB1 alterations have been described
as a major driver of primary resistance to PD-1 blockade in
KRAS-mutant lung adenocarcinoma (31, 35).
Supporting this, a recent study (36) showed that among
377 non-squamous NSCLC patients treated with platinum-
doublet chemotherapy (carboplatin or cisplatin and pemetrexed)
plus pembrolizumab (anti-PD1), the therapy response was
significantly associated with the genetic status of STK11.
Specifically, patients with genomic alterations of STK11
(N = 102) were associated with significantly shorter PFS (4.8
vs. 7.2 months, HR 1.5, 95% CI 1.1–2.0; P = 0.0063) and
shorter overall survival (10.6 vs. 16.7 months, HR 1.58, 95% CI
1.09–2.27; P = 0.0083) compared with patients without STK11
alteration (N = 275). Also, the objective response rate (RR) was
significantly different between the two groups (32.6 vs. 44.7%,
P = 0.049). More importantly, the addition of pembrolizumab
to platinum-doublet chemotherapy did not significantly improve
PFS (4.8 vs. 4.3 months, HR 1.13, 95% CI 0.83–1.54, P = 0.75) or
overall survival (10.6 vs. 10.3 months, HR 1.03, 95%CI 0.71–1.49,
P = 0.79) compared to the chemotherapy alone (36). This study
defines a subgroup of patients with STK11 alterations who do
not benefit from immunotherapy, indicating the importance
of cancer genetic information for stratification of patients who
would benefit from immune checkpoint blockade. Apparently,
co-occurring alterations further increase the heterogeneous
complexity, which may explain inconsistent outcomes of clinical
trials with KRAS-mutant lung cancers.
NEW HORIZONS FOR TREATING
KRAS-MUTANT LUNG CANCER
Refocusing on Direct Targeting of KRAS
For decades, KRAS was considered undruggable due to its high
affinity for GTP and the lack of a clear binding pocket. Enormous
attempts and efforts had been made, but all failed to identify
compounds that could effectively and directly target mutant
RAS. Since then, there has been little advance. However, with
new technologies in drug development and novel mechanistic
insights into RAS biology, attention has been refocused on
the approach that directly interferes with the function of RAS
oncoproteins, with more effort given to find the way to target
mutant alleles specifically.
Earlier studies have identified small molecules selectively
recognizing and irreversibly inactivating one specific KRAS-
mutant allele harboring a G12C amino acid substitution (37, 38).
A breakthrough of direct RAS targeting was finally made by
Ostrem et al., who, by using a novel screening technology called
tethering, developed a new strategy to target mutant KRASG12C
specifically without affecting the wild-type protein (37). This
work also suggested that the previous perception of mutant
KRASwas persistently locked in its active GTP-bound statemight
not be true.
Later on, Lim et al. reported the synthesis of a GDP analog,
SML-8-73-1, which contains an electrophilic chloroacetamide
attached to the β-phosphate. This analog can covalently modify
cysteine 12 of KRasG12C and, as a result, it competes with
GTP and GDP for active site binding in a cellular context
(38). Despite the pioneering development of the KRASG12C-
specific inhibitors, follow-up studies indicated that these initial
compounds showed only limited potency (39, 40). In a
search for more effective compounds or analogs, ARS853 was
developed (40), which selectively reduced KRAS-GTP levels
by more than 90% and increased the in vitro hydrolytic
reaction rate by 600-fold compared to the initial compound
used in Ostrem et al. (37). At the micromolar range, ARS853
potently suppressed MAPK and PI3K-AKT signaling. Thus,
KRASG12C mutant protein is in a dynamically rather than a
statically active state and targeting the inactive, GDP-bound
form of KRAS is a realistic and promising anti-RAS therapeutic.
These striking findings were recently translated into in vivo
studies, in which a new covalent KRASG12C-specific inhibitor,
ARS-1620, showed rapid and durable tumor regression in
mice (41).
These studies prompt a revisit to target KRAS oncoproteins
directly. Recent discoveries have enabled further development
and investigation of more compounds of this family in clinical
trials (Table 1). Encouraging phase I clinical trial data of
AMG510 (Amgen, clinical trial information: NCT03600883)
in 32 patients with KRASG12C mutation (14 with NSCLC,
19 with colorectal cancer, and 2 with appendix cancer) were
just released in ASCO 2019. Five of 10 evaluable patients
with NSCLC had a partial response, and four had stable
disease, in total achieving a disease control rate of 90% (9/10).
Additionally, 13 of 18 evaluable patients with colorectal cancer
experienced stable disease. Twenty-six patients were still under
study, and nine discontinued. Importantly, the treatment was
well-tolerated, with primarily grade 1 events (68%). Two grade
TABLE 1 | Ongoing clinical trials involving direct targeting of KRAS.
Compounds Company Mechanism Clinical trial
AMG
510
Amgen/Carmot
Therapeutics
KRASG12C
inhibitor
NCT03600883
MRTX849 Mirati (ex Array) KRASG12C
inhibitor
NCT03785249
KRAS
TCR
Gilead (ex
Kite/NCI)
Anti-KRASG12D
engineered T-cell
receptor
NCT03745326
AZD4785 AstraZeneca/Ionis KRAS antisense
oligonucleotide
NCT03101839
Frontiers in Oncology | www.frontiersin.org 5 September 2019 | Volume 9 | Article 953
Yang et al. Targeting KRAS-Mutant Lung Cancer
3 treatment-related AEs were reported (anemia and diarrhea).
No grade 4 or more severe treatment-related adverse effects
were reported. MRTX849 is another potent, highly selective,
and orally available small-molecule inhibitor of KRASG12C (42).
MRTX849 shows broad-spectrum anti-tumor activity in a panel
of patient- and cell-derived in vivo tumor models with KRAS
G12C-substitution, with complete tumor regression observed in
a subset of these models.
Different from the inhibitors that directly target mutant
KRAS, AZD4785 is a KRAS antisense oligonucleotide that targets
the KRAS gene irrespective of its mutation status (43). Despite
AZD4785 being safe and well-tolerated, the first phase I trial
failed, which might be due to the fact that AZD4785 targets both
mutant and wild-type KRASmRNA for degradation.
Tran and colleagues described a case of a patient with
metastatic colorectal cancer treated with autologous T cells
specific for mutant KRASG12D, which was restricted to the
major histocompatibility complex class I allele HLA-C∗08:02
(44). Despite the rarity of HLA-C∗08:02, this study demonstrated
the promise of T-cell–based immunotherapy for targeting
KRASG12D and HLA-C∗08:02. Further evaluation in more
patients is warranted.
Whether direct inhibition of KRAS with these new
compounds is sufficient remains a question, given the presence of
KRAS independence in tumor cells harboring KRAS mutations.
Concurrent inhibition of collateral dependencies may be
required to potentiate the effectiveness of those compounds.
Reinforcing MEK Inhibitors
To date, most efforts to treat cancers with RAS mutations have
focused on targeting downstream effectors of mutant RAS, such
as RAF, MEK, or PI3K, each of which is druggable. Although,
as described above, different KRAS mutations show a preference
for activating different downstream signaling, hyperactivation
of the mitogen-activated protein kinase (MAPK) pathway is
generally recognized as a key feature in KRAS-driven lung cancer
cells. One reason is that the G12C substitution (44%), the most
common subtype in KRAS-mutant lung cancer, shows more
prominent engagement with MAPK signaling. Supporting these
findings, we performed pooled drug sensitivity analysis based
on publicly available dataset in Genomics of Drug Sensitivity
in Cancer, which revealed that, compared with KRAS-wild-type
lung cancer cells, KRAS-mutant lung cancer cells are exclusively
more sensitive to various MEK inhibitors rather than those
targeting other oncogenic pathways (Figure 3). This explains
why MEK inhibitors have been the most widely investigated,
typically as a combination therapy, despite the presence of
multiple inhibitors that are being explored to target different
KRAS-activated pathways.
Rethinking Combination Treatment With
Chemotherapy
In the clinic, conventional chemotherapy is widely used to treat
patients with KRAS-mutant NSCLC, although chemotherapy
plus immune checkpoint blockade has been recently approved
as the first-line regimen for NSCLC, including patients with
KRASmutations (45, 46). Clinical trials evaluating the efficacy of
selumetinib, a potentMEK inhibitor, to potentiate chemotherapy,
have recently been conducted.
A survival benefit of selumetinib plus docetaxel in comparison
with docetaxel alone was demonstrated in a phase II clinical
trial (47). Specifically, the primary endpoint of the study—
median overall survival—was 9.4 months for the combination
(selumetinib plus docetaxel) compared with 5.2 months for the
control (placebo and docetaxel), although this difference was
not statistically significant [hazard ratio (HR) for death 0·80,
80% CI 0·56–1·14; one-sided p = 0·21]. The median PFS was
significantly improved in patients receiving selumetinib (5.3 vs.
2.1 months; HR for progression 0·58, 80% CI 0·42–0·79; one-
sided p = 0·014) as was the response rate (37% vs. 0%; p <
0·0001). Subsequently, a subgroup analysis demonstrated that
patients harboring G12V and G12C KRAS mutations appeared
to experience higher RR and longer PFS for the combination
arm, which was recently confirmed in preclinical mouse
model (17).
Following this encouraging result, a further phase III
clinical trial in KRAS-mutant lung cancer was conducted,
which, however, failed to reproduce the significant benefit in
patients treated with the combination compared with docetaxel
alone (48). In this larger cohort trial, median PFS was 3.9
months with the combination group and 2.8 months with
the control group (difference, 1.1 months; HR, 0.93 [95%
CI, 0.77–1.12]; P = 0.44). Median overall survival was 8.7
and 7.9 months, respectively (difference, 0.9 months; HR,
1.05 [95% CI, 0.85–1.30]; P = 0.64). There is a marginally
significant objective RR (20.1% in combination group vs.
13.7% in the control group; odds ratio, 1.61 [95% CI, 1.00–
2.62]; P = 0.05). Whereas, the inconsistency with previous
phase II trial results was unclear, a multitude of possible
mechanisms, such as the aforementioned genomic (diverse
point mutations and co-occurring alterations) and phenotypic
(different EMT status) heterogeneity within the recruited
patients, might be anticipated. In addition, chemotherapeutics
used for combination treatment may need to be reconsidered
in future studies, given that distinct amino acid substitutions of
KRAS oncoproteins differed in their response to the commonly-
used chemotherapy agents (9, 11). Nonetheless, these results
did not rule out the effectiveness of this combination therapy
in a subgroup of patients with KRAS mutations and deserved
more detailed analysis, which might provide mechanistic
information that facilitates patient stratification and prediction of
potential responders.
Trametinib is another selective and potent MEK inhibitor
that has been clinically approved for BRAF mutant cancers
(mainly melanoma). Like selumetinib, the efficacy of trametinib,
alone or in combination with docetaxel, has been evaluated
in KRAS-mutant NSCLC. In a phase II trial, trametinib as
a monotherapy showed RR and PFS similar to docetaxel in
previously treated KRAS-mutant NSCLC (49). Another phase
II study with KRAS-mutant NSCLC (n=54, including 19 with
G12C, 9 with G12D, 9 with G12A) documented a trend toward
worse PFS (HR = 1.86, p = 0.06) and survival (HR=1.80,
p = 0.14) in G12C patients compared to non-G12C patients
(50). Trametinib plus docetaxel had a RR of 33% and median
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FIGURE 3 | MEK mediates the key downstream effect in KRAS-mutant lung cancer cells. (A) Drug information incorporated in the Genomics of Drug Sensitivity in
Cancer database. (B) Integrative analysis of drug sensitivity data of KRAS-mutant (n = 20) lung adenocarcinoma cells compared to KRAS-wild-type (WT; n = 40)
ones. In the volcano plot, the x-axis indicates the IC50 effect, with effect < 0 representing KRAS-mutation sensitive inhibitors (in blue) compared with KRAS-WT ones.
The color intensity and the circle size are proportional to significance value (the y-axis). (C) Sensitivity analysis of KRAS-mutant (in red) and WT (in blue) cells to one of
the MEK inhibitors, refametinib.
survival of 11.1 months in patients with recurrent KRAS-mutant
NSCLC. These results suggest that clinical responses to combined
trametinib and docetaxel may differ between G12C and non-
G12C patients.
Rewiring SHP2 Activities
SHP2 is a non-receptor protein tyrosine phosphatase, encoded by
the PTPN11 gene that is ubiquitously expressed. SHP2 is involved
in signal transduction downstream of multiple growth factors,
cytokine, and integrin receptors and, not surprisingly, functions
as an essential player in oncogenesis (51, 52). Upon the activation
of RTKs, the SH2 domain of SHP2 binds to the phosphorylated
tyrosine residues and various substrates, such as RTKs, scaffolds
and adaptor proteins, which enables SHP2 in its active state for
enzymatical removal of phosphates (dephosphorylation) from
the substrates.
Previous studies demonstrated that the adaptive reactivation
of MAPK signaling in the presence of a MEK inhibitor was
mediated by the loss of MAPK-dependent negative feedback
loops and the consequent induction of RTKs signaling (26,
53). Recent studies in KRAS-mutant lung cancer (54, 55)
and pancreatic adenocarcinoma (55), KRAS-amplified gastric
carcinoma (56), and multiple other cancer models expressing
mutant or wild-type KRAS (57, 58) revealed that the anti-
tumor effect of MEK inhibitor treatment could be dramatically
potentiated by concurrent SHP2 inhibition.
Specifically, targeting of MEK alone is frequently hampered
by adaptive resistance, which is complex and context-dependent,
and can involve activation of various RTKs, including ERBB
family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62). Strikingly,
SHP2, the key integrator of RTK-RAS signaling, was necessary for
various contexts uponMEK blockade and required to re-establish
MAPK signaling. Strong synergy was observed when SHP2
and MEK were simultaneously targeted, resulting in sustained
inhibition of tumor growth in different cancer models.
These studies provided compelling evidence supporting
further investigations of combining SHP2 and MEK inhibitors
for patients with KRAS-mutant cancer. Fitting this tendency,
the recent development of potent allosteric SHP2 inhibitors
strengthens the interest in targeting SHP2 in cancer (63). A
clinical trial (NCT03114319) investigating TNO155, an SHP2
inhibitor, in patients with K-/N-/H-RAS, BRAF, or PTPN11
mutant tumors is ongoing.
Resurging Autophagy Inhibition
Potential therapeutic interventions to inhibit autophagy have
been extensively studied in cancer. Tumor cells depend on
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macroautophagy to cope with oncogene-induced metabolic
stress. Notably, in human cancer cell lines or tumors bearing
KRAS mutations, high levels of basal autophagy were observed,
making inhibition of autophagy therapeutically actionable in
KRAS-driven tumors (64, 65).
Three simultaneously published studies signal a resurgence
of interest to inhibit autophagy in KRAS-driven cancer (66–
68). These studies indicated that upon the inhibition of the
MAPK pathway, KRAS-mutant tumors depend on autophagy
for survival and that, as a result, blocking this protective
mechanism by concomitant inhibition of autophagy and MEK
or ERK kinases is likely to be therapeutically beneficial in
patients with KRAS-mutant pancreatic ductal adenocarcinoma,
NRAS-mutant melanoma, and BRAF-mutant colorectal cancer
(66, 67). More importantly, Kinsey et al. initiated off-label
treatment for a patient with metastatic PDAC with trametinib
and hydroxychloroquine, both of which have been clinically
approved for other indications. They observed a striking disease
response with a 50% reduction in tumor burden without
toxicity (67).
Based on the intriguing findings, further clinical investigations
are required to determine the benefits of combined MEK and
autophagy for patients with activating mutations in the RAS–
RAF–MEK–ERK pathway.
Rewiring KRAS Activation
In normal cases, KRAS is activated in response to signaling from
upstream RTKs. However, oncogenic KRAS mutations “lock”
the protein in a constitutively active state, activating KRAS-
dependent signaling in a RTKs-independent pattern. In line with
this, clinical trials confirmed that patients with KRAS-mutant
cancers generally have a poor response to the first generation of
EGFR inhibitors, such as erlotinib and gefitinib, and the presence
of KRASmutations is used as a biomarker to exclude patients for
EGFR inhibitor therapy (7, 8, 69).
However, recent studies have challenged this paradigm, which
instead demonstrated that the activation of ERBB signaling was
required for KRASG12D-driven lung tumorigenesis in preclinical
mice models and that pan-ERBB inhibition other than EGFR
inhibition alone was strikingly effective to inhibit KRAS-mutant
tumor growth and progression (61, 62).
In humans, the ERBB family contains HER1 (EGFR, ERBB1),
HER2 (NEU, ERBB2), HER3 (ERBB3), and HER (ERBB4).
Previous studies showed that ERBB3 activation was associated
with resistance to MEK inhibition in KRAS-mutant NSCLC
cells (26, 59). In a recent study by Kruspig et al. (61), the
authors showed that multiple ERBB ligands (e.g., Areg, Ereg,
Nrg3, Nrg4, and Hbegf) and receptors (for example, Erbb2 and
Erbb3) were highly expressed in a KRASG12D mouse model.
Neratinib, a multi-ERBB inhibitor (70, 71), almost completely
suppressed the emergence of tumors. In sharp contrast, erlotinib
failed to reproduce the same effect. Further mechanistic analyses
of seemingly contradictory results revealed that ERBB activity
establishes a feed-forward loop to amplify signaling through the
core RAS-ERK cascade to sustain survival and proliferation in
KRAS-mutant NSCLC. Indeed, pan-ERBB inhibition enhanced
the potency of MEK inhibition in vitro and in vivo.
Similarly, an independent study by Moll et al. demonstrated
a requirement for ERBB signaling to support the progression of
KRASG12D-driven lung cancer (62). In this study, an independent
pan-ERBB inhibitor, afatinib, was used. Genetic mouse models
revealed that EGFR deletion attenuates mutant KRAS activity
and transiently reduces tumor growth. However, EGFR
inhibition initiated a rapid resistance mechanism involving
non-EGFR ERBB family members, which triggered a tumor
escape mechanism. This provided an explanation, at least to
some extent, for the poor unresponsiveness of KRAS-mutant
lung cancer patients to the first-generation TKIs targeting EGFR
alone. More importantly, afatinib blocked compensatory ERBB2
and ERBB3 activation, whereas erlotinib and gefitinib did not.
Together, these studies suggested the therapeutic potential of
pan-ERBB inhibitors in KRAS-driven tumors.
Notably, both studies revealed a requirement for simultaneous
inhibition of multiple ERBB while targeting a single member of
the family was not effective. These preclinical studies provide
new insights into KRAS-driven tumorigenesis and bring new
hope for KRAS-mutant lung cancer patients. Further trials,
such as combined MEK with pan-ERBB inhibitors, are highly
needed to determine the translational significance of the pan-
ERBB inhibition strategy for patients, which can be easily and
quickly conducted given that both inhibitors have been clinically
approved (72, 73).
Re-examining Downstream Partnership:
CRAF (RAF1) but Not A-RAF or B-RAF
KRAS oncogenes signal through a cascade of downstream
effectors, among which the most important one is the
RAF/MEK/ERK cascade. The direct RAS downstream effectors
within the RAF/MEK/ERK pathway are the RAF kinases,
including A-, B-, and C-RAF. However, it is not well-known how
these individual RAF kinases contribute to KRAS-mutant tumor
initiation and development.
Recent studies showed that C-RAF rather than B-RAF plays
a crucial role in mediating KRAS oncogenic signaling (74,
75). Targeting of C-Raf rather than of B-Raf kinase could
recapitulate the effect of Kras ablation and effectively inhibit
tumor development without inducing significant toxicities in
mouse models of Kras/Trp53-mutant lung adenocarcinoma. This
work suggested that distinct RAF kinases likely play different
roles in mediating KRAS oncogenic signaling.
In a more recent study, ablation of B- or C-RAF was
concomitant with KrasG12V induction (76). C-Raf ablation
completely prevented Kras-driven NSCLC without inducing
deleterious effects, which, however, was not the case with B-
Raf ablation, indicating that B-Raf is dispensable for Kras
oncogenic signaling. Moreover, ablation of C-Raf did not affect
Mek or Erk phosphorylation, suggesting that C-Raf-mediated
Kras signaling is independent of the MAPK cascade. Further,
the same group showed that combined inhibition of C-Raf
and Egfr induced complete regression of pancreatic ductal
adenocarcinomas in Kras/Trp53-driven GEM models and PDXs
without apparent toxicity (77). Together, these studies provided
compelling evidence that C-Raf, but not B-Raf or A-Raf, may
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mediate the oncogenic signaling in KRAS-driven cancer. More
importantly, the therapeutic effect observed by ablation of C-Raf
was likely due to disrupting the interaction of the C-Raf protein
with other partners, such as BCL2, ASK1, MST2, and ROKα (76),
whereas not via modulating MAPK cascade that is also essential
for normal homeostasis. This might explain, to some extent, why
the elimination of C-Raf did not induce systemic toxicity, in
contrast to MEK inhibitors.
Notably, the therapeutic effect achieved by C-Raf ablation
could not be reproduced by three C-Raf inhibitors that are
designed to block the kinase activity other than the protein
expression, confirming that the non-kinase activity of C-RAF
instead of the conventional MAPK cascade is critical for
the ability of KRAS-dependent oncogenic transformation. The
striking finding of these studies, which is at odds with the
currently ongoing efforts to develop C-RAF kinase inhibitors,
implies, instead, the need for strategies to block C-RAF kinase-
independent activities or induce its degradation.
Revitalizing Chemotherapy
Currently, the platinum-based chemotherapy is still widely used
for patients with KRAS-mutant lung cancer. However, the
efficacy of chemotherapy is very limited, and durable response
is generally short. Considerable efforts have been made to
potentiate the efficacy of chemotherapy in KRAS-mutant cancer.
Unfortunately, a recent phase III study has once again frustrated
this attempt, which showed no additional survival benefit from
combined MEK inhibitors compared to docetaxel alone (48).
Oncogenic KRAS signaling also involves PI3K-AKT-mTOR,
via the interaction with the catalytic subunits of PI3K (78–
80). Blocking RAS-mediated PI3K activation has also shown to
inhibit the progression of KRAS-driven tumors. However, high
toxicities of targeting PI3K, AKT or mTOR, in combination with
MEK inhibitors, have prevented their approval for use in human
patients (81–83).
We recently found that activation ofmTOR signalingmediates
a key resistance mechanism to chemotherapy in KRAS-mutant
lung cancer (84). We observed exclusively hyperactivated mTOR
signaling in lung cancer patient samples with KRAS-mutations
but not in those carrying wild-type KRAS. Combined clinically
approved mTOR inhibitor and chemotherapy showed a strong
synergism in inhibiting proliferation of cancer cells harboring
KRAS-mutation specifically. Additionally, the efficacy of this
combination treatment correlates with the magnitude of mTOR
activity induced by chemotherapy alone. Our results pinpoint a
rational and readily translatable strategy that combines mTOR
inhibitors with standard chemotherapy to treat KRAS-mutant
lung cancer.
A recently published study provided novel hints to potentiate
platinum-based chemotherapy in multiple cancer types (85).
Jin et al. used multi-step kinome screens and identified
MAST1, an AGC serine/threonine protein, as a key mediator of
cisplatin resistance. The mechanistic study showed that MAST1
expression was increased in resistant cells and functioned as
a MAP3K (MAPK kinase kinase), thereby activating MEK1
in cisplatin-resistant cells. Knockdown of MAST1 re-sensitized
the resistant cells to cisplatin in vitro and in vivo. Further
investigations showed that cisplatin directly binds to cysteine
142 site of MEK1, restricting its access to C-RAF that typically
phosphorylates MEK1. In this case, MAST1 took over C-RAF
to re-activate MAPK cascade in cisplatin-resistant cells, and
inhibition of MAST1 led to decreased MEK1 phosphorylation,
explaining the effectiveness of targeting MAST1 in overcoming
cisplatin resistance. More interestingly, MAST1 expression
was shown to be specific to cisplatin rather than other
similar agents (for instance, 5-fluorouracil) that interfere with
DNA replication. This finding may be particularly relevant
in the oncogenic RAS/BRAF setting, which mainly activates
downstream MAPK signaling.
In a recent study (86), we reported that pemetrexed-
resistant KRAS-mutant lung cancer cells assume a mesenchymal
phenotype and cross-resist MEK inhibitors. Mechanistically,
acquisition of resistance enables KRAS-mutant lung cancer
cells to bypass canonical KRAS effectors but entail hyperactive
AXL/eIF4E, increased protein turnover in the endoplasmic
reticulum (ER), and adaptive activation of an ER stress-relief
unfolded protein response survival pathway whose integrity is
maintained by HSP90. In line with these mechanistic findings,
HSP90 inhibitors synergistically enhance antitumor effects of
pemetrexed and MEK inhibitors in multiple in vitro and in
vivo models, validating a rational combination strategy to treat
KRAS-mutant lung cancer.
Reactivating Anti-tumor Immunity
Immune surveillance is generally dormant in cancer via
dysregulation of immune checkpoints, such as the upregulation
of the immunosuppressive protein PD-L1 for the evasion of
the host immune system. Considerably convincing evidence
has shown the importance of immune checkpoint blockade for
treating various cancers (87). However, the therapeutic efficacy
varies individually due to the high heterogeneity of tumors and
the lack of reliable biomarkers to stratify the patients. Currently,
limited biomarkers, such as PD-L1 expression (88) and tumor
mutation load (TMB) (89–91), are clinically used to predict the
immunotherapy benefit.
Interestingly, several preclinical studies suggested that
tumors harboring KRAS mutations might be associated with
a vulnerability to immunotherapies, in particular those with
concomitant TP53 mutations (29, 92, 93). Mechanistic studies
indicated that oncogenic KRAS could stabilize PD-L1 mRNA
through post-transcriptional modifications of the AU-rich
element binding protein tristetraprolin (TTP) (94). Specifically,
KRAS-MEK signaling contributes to phosphorylation and
inhibition of TTP through the kinase MK2. In the same study, a
high correlation between MAPK activation and elevated PD-L1
expression was observed in KRAS-mutant human lung and
colorectal tumors.
A landmark trial (KEYNOTE-024) demonstrated that
pembrolizumab was superior to chemotherapy in advanced
NSCLC (potentially including patients with KRAS-mutations),
among which more than 50% had high PD-L1 expression
(95). Follow-up studies of the KEYNOTE-024 cohort
revealed continuous survival benefit in patients treated with
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pembrolizumab as first-line monotherapy compared to those
treated with chemotherapy (96).
Importantly, two remarkable phase III trials (KEYNOTE-
189 and KEYNOTE-407) demonstrated that addition of
pembrolizumab (Keytruda, anti-PD1) could significantly prolong
the survival of NSCLC patients (45, 97). The promising results
from these studies have led to the approval of pembrolizumab
in combination with chemotherapy (carboplatin-pemetrexed)
for metastatic, non-squamous NSCLC, and the approval of
pembrolizumab in combination with chemotherapy (carboplatin
and Taxol) for patients with squamous lung carcinoma,
excluding those carrying EGFR or ALK mutations. Although
patients with KRAS-mutant NSCLC were potentially included in
the two studies, specific efficacy of the combination therapy on
KRAS-mutant NSCLC remains to be investigated.
A recent systematic review and meta-analysis study, which
integrated multiple randomized clinical trials, showed that
immune checkpoint inhibitors significantly prolonged overall
survival in the KRAS-mutant subgroup (HR, 0.65; 95% CI,
0.44–0.97; P = 0.03) but not in the KRAS wild-type one (HR,
0.86; 95% CI, 0.67–1.11; P = 0.24; interaction, P = 0.24) (98).
Another meta-analysis study that incorporated 509 patients (138
of KRAS-mutant and 371 with KRAS-wild-type NSCLC) showed
that, compared to docetaxel chemotherapy, immune checkpoint
inhibitors improved overall survival in patients with previously-
treated KRAS-mutant NSCLC (HR = 0.64 [95% confidence
interval, 0.43–0.96], P = 0.03) (99), but not in patients with
wild-type KRAS (HR = 0.88 [95% confidence interval, 0.68–
1.13], P = 0.30). These results indicate that KRAS mutational
status is a potential biomarker for survival benefits to immune
checkpoint inhibitors. However, two other studies with advanced
non-squamous NSCLC reported that the efficacy of immune
checkpoint inhibitors is independent of KRAS-mutant status
(100, 101). Thus, further studies with a stratification of KRAS
genetic status are still needed.
Although, preclinical studies using immune-competent
mouse models verified the promising efficacy of checkpoint
blockade in the Kras-mutant setting (92, 102, 103), a majority
of these studies relied on mouse models with a single genetic
background, which limits the power to assess the potential
influence of other co-occurring mutations (e.g., STK11
alterations). Co-occurring genetic mutations, which can lead
to differential downstream effectors engaged by mutant KRAS,
have been reported to significantly affect the tumor immune
signatures (25, 29, 31, 35) and responses to immunotherapy (30).
This might explain why a pooled analysis of patient response
data does not consistently support the association between
benefits of immunotherapy and KRASmutations (98–101).
CONCLUSIONS
Targeting KRAS has represented a tremendous unmet clinical
need. Nevertheless, the challenge of clinical treatment of KRAS-
mutant cancers seems not to be insurmountable. Now, a new
wave of attempts is motivated to target KRAS directly, which
has long been considered undruggable. A striking response
has been achieved with AMG510 in patients with KRASG12C.
New treatment strategies based on a deeper understanding
of the pathobiology of oncogenic KRAS, such as abolishing
C-RAF, blocking the universal rewiring of SHP2, and the
protective autophagy in response to MEK inhibitors are
highly promising with preliminary success in human patients.
Conventional approaches, such as combined chemotherapy
and mTOR inhibitors, as well as combined cisplatin and
MAST1 inhibitors, are also encouraging but require further
investigations in patients. The great success of immunotherapy
has been witnessed in the treatment of patients with various
tumors, but more evidence is required in cancer patients with
KRASmutations.
Given the presence of a variety of potent and specific
chemicals, treating KRAS-mutant lung cancer remains a
significant challenge, implying that the problem might be
mechanism-related rather than the efficacy of targeting itself.
A critical point is a high heterogeneity within KRAS-mutant
tumors. To maximize the patient benefit, it cannot be more
important than molecularly guided stratification on top of
KRASmutations.
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